WEBULL
News
BCRX
6.84
+4.43%
0.29
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight
Simply Wall St · 11h ago
BioCryst Pharmaceuticals To Present Nine Abstracts From Hereditary Angioedema Portfolio At 2026 AAAAI Annual Meeting
Benzinga · 1d ago
BioCryst Unveils Positive New HAE Data for ORLADEYO and Navenibart at AAAAI 2026
Reuters · 1d ago
Weekly Report: what happened at BCRX last week (0202-0206)?
Weekly Report · 3d ago
Is Biocryst Pharmaceuticals (BCRX) Attractively Priced After Extended Share Price Weakness?
Simply Wall St · 4d ago
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent
Simply Wall St · 5d ago
BioCryst reports inducement grants under Nasdaq listing rule
TipRanks · 02/05 12:17
BioCryst Pharmaceuticals kündigt Veröffentlichung neuer Finanzergebnisse an
Reuters · 02/05 12:03
BioCryst Pharmaceuticals Inc. to Report Fourth Quarter Financial Results
Reuters · 02/05 12:03
BioCryst Pharmaceuticals gewährt neuen Mitarbeitern Aktienoptionen und RSUs als Teil des Vergütungsplans
Reuters · 02/05 12:00
BioCryst Grants Stock Options and RSUs to New Employees Under Inducement Plan
Reuters · 02/05 12:00
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/05 12:00
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
Barchart · 02/05 06:01
Weekly Report: what happened at BCRX last week (0126-0130)?
Weekly Report · 02/02 09:50
BioCryst Pharmaceuticals Price Target Cut to $13.00/Share From $14.00 by RBC Capital
Dow Jones · 01/30 15:44
BioCryst Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 01/30 15:44
RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13
Benzinga · 01/30 15:34
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX)
TipRanks · 01/30 12:21
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)?
Simply Wall St · 01/28 01:36
BioCryst Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Jill C. Milne
Reuters · 01/27 22:19
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.